


Serum Levels of Tumor Necrosis Factor- α and Vascular Endothelial Growth Factor in the Subtypes of Clinical High Risk Individuals: A Prospective Cohort Study [Response to Letter]

JiaYi Ye, TianHong Zhang 

Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China

Correspondence: TianHong Zhang, Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai Engineering Research Center of Intelligent Psychological Evaluation and Intervention, Shanghai Key Laboratory of Psychotic Disorders, Shanghai, 200030, People's Republic of China, Tel +86-21-34773065, Fax +86-21-64387986, Email zhang_tianhong@126.com

Dear editor

We thank Authors Lienggonegoro, Dany, and Panjaitan for their thoughtful replies to our article.

Lienggonegoro et al reinforce our initial findings regarding the involvement of inflammatory processes in the pathophysiology of mental illnesses, particularly schizophrenia. They also underscore the significance of tumor necrosis factor- α (TNF- α) and vascular endothelial growth factor (VEGF) in psychiatric disorders, providing valuable insights into subclinical inflammation and neuroinflammation associated with psychosis.

Lienggonegoro et al provided valuable input regarding the role of TNF- α in immunological and physiological processes, particularly its connection with obesity. We conducted further analyses to explore the relationship between BMI and TNF- α levels among our study participants. However, we did not observe significant differences or correlations between these variables. One possible explanation could be that our sample did not receive medication at the time of enrollment, which might have mitigated the impact of medication-induced metabolic syndrome. Past research has indeed demonstrated the influence of antipsychotic medications on TNF- α levels.¹ The interplay among these three factors may be complex, and our cohort is currently undergoing follow-up assessments. Some participants will commence medication treatment, and we intend to report on the relationships between these factors in our future research.

In our study, the primary focus was on examining the differences in TNF- α and VEGF levels among clinical high risk (CHR) for psychosis subgroups with different clinical characteristics, particularly those categorized based on positive and negative symptoms. We appreciate your suggestion and have indeed conducted repeated measures analysis of variance analysis as advised. However, the results did not show any statistically significant effects of Time, Group, or their interaction (Time \times Group) on TNF- α and VEGF levels. One potential explanation for this might be related to the data collection process during the longitudinal follow-up. Unfortunately, due to the impact of the COVID-19 pandemic, blood sample collection was completed for only 65 participants, as many patients were unable to attend in-person visits. As we continue our research, we plan to address this issue by collecting blood samples at multiple time points to provide a more comprehensive understanding of these factors.

In our study, we conducted measurements for both serum levels of TNF- α , VEGF, and complement proteins. Our findings indicated that serum complement proteins, rather than inflammatory factors, were effective in predicting psychosis.² The serum levels of TNF- α and VEGF for each sample were measured in duplicate using an enzyme-linked immunosorbent assay (ELISA) with the Human HS Cytokine Premixed Kit. This was done following the manufacturer's instructions.

In summary, our ongoing follow-up within the Shanghai At Risk for Psychosis-extended (SHARP-extended) program³⁻⁵ for at-risk individuals continues to yield valuable insights. Growing evidence suggests that longitudinal data collected at multiple time points may hold significant value in understanding the onset of mental illnesses.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Lin C, Chen K, Yu J, et al. Relationship between TNF-alpha levels and psychiatric symptoms in first-episode drug-naive patients with schizophrenia before and after risperidone treatment and in chronic patients. *BMC Psychiatry*. 2021;21(1):561. doi:10.1186/s12888-021-03569-5
2. Zhang T, Zeng J, Ye J, et al. Serum complement proteins rather than inflammatory factors is effective in predicting psychosis in individuals at clinical high risk. *Transl Psychiatry*. 2023;13(1):9. doi:10.1038/s41398-022-02305-1
3. Zhang T, Tang X, Zhang Y, et al. Multivariate joint models for the dynamic prediction of psychosis in individuals with clinical high risk. *Asian J Psychiatr*. 2023;81:103468. doi:10.1016/j.ajp.2023.103468
4. Zhang T, Zeng J, Wei Y, et al. Changes in inflammatory balance correlates with conversion to psychosis among individuals at clinical high-risk: a prospective cohort study. *Psychiatry Res*. 2022;318:114938. doi:10.1016/j.psychres.2022.114938
5. Zhang T, Wang J, Xu L, et al. Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals. *Eur Arch Psychiatry Clin Neurosci*. 2022;272(4):591–602. doi:10.1007/s00406-021-01331-2

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Neuropsychiatric Disease and Treatment 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Neuropsychiatric Disease and Treatment editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Neuropsychiatric Disease and Treatment

Dovepress

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>

<https://doi.org/10.2147/NDT.543907>